HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schick lawsuit

This article was originally published in The Rose Sheet

Executive Summary

Bridgeport, Conn. federal court denies Gillette's motion for clarification of a May 31 preliminary injunction limiting certain claims for firm's M3 Power packaging and advertising, Energizer reports in June 21 statement. Among the claims in question were that M3 Power "micro-pulses raise hair up and away from skin" (1"The Rose Sheet" June 6, 2005, p. 7). Gillette's request for clarification argued preliminary injunction did not prohibit the claim micro-pulses "stimulate" hair up and away from skin and that it did not apply to packages already at retail stores, according to Energizer. The judge disagreed, however, noting the court "specifically addressed 'raises up and away' as literally false in its May 31, 2005 ruling," and "the word 'stimulates' does not alter the meaning when used in conjunction with 'up and away,'" Energizer says. Gillette rival filed a motion for preliminary injunction against the firm in January...

You may also be interested in...



Court Enjoins Gillette From Making Certain M3 Power Ad Claims

Gillette must remove or cover words and visual images on packaging for the M3 Power shaver claiming the razor, its micro-pulses or oscillations change the angle of the hair in relation to the skin, a Bridgeport, Conn. federal court ruled May 31

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel